Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| MOVE | Movano | $17.80 | $10.83 | 155.40% | 30.8M | $6.3M | $4.67$55.00 |
| BNAI | Brand Engagement Network | $13.92 | $5.26 | 60.74% | 7M | $39M | $1.18$14.18 |
| CHRS | Coherus Oncology | $2.12 | $0.53 | 33.34% | 7.8M | $192M | $0.71$2.15 |
| RVYL | Ryvyl | $6.91 | $1.67 | 31.87% | 10.8M | $5.4M | $4.50$81.55 |
| GIBO | Gibo | $2.33 | $0.56 | 31.75% | 27.2M | $6.4M | $1.49$1,396.00 |
| MAXN | Maxeon Solar Technologies | $3.81 | $0.85 | 28.72% | 1.1M | $50M | $2.49$6.58 |
| LIF | Life360 | $70.05 | $15.24 | 27.81% | 1.4M | $4.3B | $29.62$112.54 |
| RMCF | Rocky Mountain Chocolate Factory | $2.30 | $0.34 | 17.34% | 82.1K | $18M | $1.12$2.35 |
| SGML | Sigma Lithium | $14.71 | $2.17 | 17.30% | 3.4M | $1.4B | $4.25$16.87 |
| SOPA | Society Pass | $2.74 | $0.38 | 16.09% | 10.2M | $18M | $0.64$6.75 |
Related Articles
Featured Article
Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year
Adam Spatacco|Aug 9, 2024
Altimmune is a little-known pharmaceutical company looking to disrupt the weight loss space.
Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?
Alex Carchidi|Jul 20, 2024
At least one of the pair has a credible shot at finding a home in the market.
Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics
Alex Carchidi|Jul 10, 2024
Both competitors have promising lead programs, and enough cash, too.
3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics
Alex Carchidi|Jun 30, 2024
While their share prices have traveled different paths recently, the similarity between the two companies is striking.
If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy
Alex Carchidi|Jun 29, 2024
The market for weight loss medicines keeps getting hotter and hotter.
1 Huge Reason Solar Stocks Are Poised for a Comeback
Travis Hoium|May 1, 2024
Solar panel prices are falling and that could be good for some solar energy stocks.
This Biotech Is About to Eat AbbVie's Market Share, but Is It a Buy?
Alex Carchidi|Jun 16, 2023
Coherus' biosimilar to Humira could catapult the company to success.
Wall Street Absolutely Loved This Biotech Stock. But It Just Crashed More Than 50%.
Keith Speights|Mar 22, 2023
It's not the end of the story for this once high-flying biotech stock.
My 3 Top Biotech Stock Picks for 2023
George Budwell, PhD|Nov 22, 2022
Biotech stocks are set to shine in 2023.
This Under-the-Radar Solar Stock Is Growing Fast
Rekah Khandelwal|May 3, 2022
The company's solar module shipments rose 76% year over year in the first quarter.
